Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: Proposal for a new nomenclature

Journal of Human Genetics

Volumn 53, Issue 3, 2008, Pages 201-209

  Yuliwulandari, Rika ^a,b   Sachrowardi, Qomariyah ^b   Nishida, Nao ^a   Takasu, Miwa ^a   Batubara, Lilian ^b   Susmiarsih, Tri Panjiasih ^b   Rochani, Jecti Teguh ^b   Wikaningrum, Riyani ^b   Miyashita, Risa ^a   Miyagawa, Taku ^a   Sofro, Abdul Salam Mudzakir ^b   Tokunaga, Katsushi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YARSI UNIVERSITY   (Indonesia)

Author keywords

Acetylation; Indonesian; NAT2; Polymorphisms; Promoter

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ACETYLATION; ADULT; AGED; ALLELE; ARTICLE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENE STRUCTURE; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INDONESIA; LINKAGE ANALYSIS; MALE; NOMENCLATURE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PROMOTER REGION; SEQUENCE ANALYSIS; SOUTHEAST ASIA;

ADOLESCENT; ADULT; AGED; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; DNA PRIMERS; FEMALE; HUMANS; INDONESIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REFERENCE VALUES; TRANSCRIPTION, GENETIC;

EID: 40049087700     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-007-0237-z     Document Type: Article

References (39)

1. Bakayev VV, Mohammadi F, Bahadori M, Sheikholslami M, Javeri A, Masjedi MR, Velayati AA (2004) Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals. Eur J Clin Pharmacol 60(7):467-471
2. Bandmann O, Vaughan JR, Holmans P, Marsden CD, Wood NW (2000) Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease. Mov Disord 15:30-35
3. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW (1993) Genotype/phenotype discordance for human arylamine N-acetyltransferase 2 (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 14:1689-1692
4. Blum M, Grant DM, McBride W, Heim M, Meyer UA (1990) Human N-acetyltransferase genes: isolation, chromosomal localisation and functional expression. DNA Cell Biol 9:193-203
5. Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88:5237-5241
6. Butcher NJ, Boukouvala S, Sim E, Minchin RF (2002) Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2:30-42
7. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581-592
8. Chen B, Zhang WX, Cai WM (2006) The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol 62:355-359
9. Evans DA, McLeod HL, Pritchard S, Tariq M, Mobarek A (2001a) Interethnic variability in human drug responses. Drug Metab Dispos 29:606-610
10. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, Kadlubar F (1999) Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 8:683-692
11. Hein DW (2006) N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25:1649-1658
12. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K (1994) Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 3:729-734
13. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphism. Cancer Epidemiol 9:29-42
14. Hickman D, Sim E (1991) N-acetyltransferase polymorphism, comparison of phenotype and genotype in humans. Biochem Pharmacol 42:1007-1014
15. Hiratsuka M, Kishikawa Y, Takekuma Y, Matsuura M, Narahara K, Inoue T, Hamdy SI, Endo N, Goto J, Mizugaki M (2002) Genotyping of the N-acetyltransferase 2 polymorphisms in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 17(4):357-362
16. Huang YS, Chern HD, Su WJ, Wu JC, Yang SY, Chang FY, Lee DS (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883-889
17. Huang CC, Chien WP, Wong RH, Cheng YW, Chen MC, Chou MC, Lee H (2007) NAT2 fast acetylator genotype is associated with an increased risk of colorectal cancer in Taiwan. Dis Colon Rectum 50:1-9
18. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW (2007) Identification of N-Acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos 35:721-727
19. Kilbane AJ, Silbart LK, Manis M, Beitins IZ, Weber WW (1990) Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 47:470-477
20. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sorgel F, Fuhr U (2005) Should we use N-Acetyltransferase type 2 genotyping to personalized isoniazid doses? Antimicrob Agents Chemother 49(5):1733-1738
21. Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J (2007) Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 63:927-933
22. Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-ard J, Warasiha B (2003) Arylamine N-acetyltransferase-2 genotypes in the Thai populations. Br J Clin Pharmacol 55:278-281
23. Lee SY, Lee KA, Ki CS, Kwon OJ, Kim HJ, Chung MP, Suh GY, Kim JW (2002) Complete sequencing of a genetic polymorphism in NAT2 in the Korean populations. Clin Chem 48(5):775-777
24. Leff MA, Fretland AJ, Doll MA, Hein DW (1999) Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem 274:34519-34522
25. Lilla C, Verla-Tebit E, Risch A, Jager B, Hoffmeister M, Brenner H, Chang-Claude J (2006) Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 15:99-107
26. Lin HJ, Han CY, Lin BK, Hardy S (1993) Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, Blacks, Hispanics, and Whites: application to metabolic epidemiology. Am J Hum Genet 52:827-834
27. Lin HJ, Han CY, Lin BK, Hardy S (1994) Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4:125-134
28. Loktionov A, Moore W, Spencer SP, Vorster H, Nell T, O'Neill IK, Bingham SA, Cummings JH (2002) Differences in N-acetylation genotypes between Caucasians and Black South Africans: implications for cancer prevention. Cancer Detect Prev 26:15-22
29. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, vanHelden PD, van der Walt BJ, Donald PR, van Jaarsveld PP (1997) Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 155:1717-1722
30. Patin E, Harmant C, Kidd KK, Kidd J, Froment A, Mehdi SQ, Sica L, Heyer E, Quintana-Murci L (2006) Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Hum Mutat 27(7):720-730
31. Rihs HP, John A, Scherenberg M, Seidel A, Brüning T (2007) Concordance between the deduced acetylation status generated by high-speed real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim Acta 376:240-243
32. Shishikura K, Hohjoh H, Tokunaga K (2000) Novel allele containing a 190C>T nonsynonymous substitution in the N-acetyltransferase (NAT2) gene. Hum mutat 15(6):581-584
33. Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Nakajima A, Mitamura T, Mimori A, Hara M, Kamatani N (2007) Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 9:1-7
34. Straka RJ, Burkhardt T, Lang NP, Hadsall KZ, Tsai MY (2006) Discordance between N-acetyltransferase 2 phenotype and genotype in a populations of Hmong subjects. J Clin Pharmacol 46:802-811
35. Tanira MOM, Simsek M, Balushi KA, Lawatia KA, Barawani HA, Bayoumi RA (2003) Distribution of arylamine N-acetyltransferase 2 (NAT2) genotypes among Omanis. SQU J Sci Res Med Sci 5(1-2):9-14
36. Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348:529-537
37. Wikman H, Thiel S, Jager B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H, Risch A (2001) Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility. Pharmacogenetics 11:157-168
38. Woolhouse NM, Qureshi MM, Bastaki SM, Patel M, Abdulrazzaq Y, Bayoumi RA (1997) Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis. Pharmacogenetics 7(1):73-82
39. Zhao B, Lee EJ, Wong JY, Yeoh PN, Gong NH (1995) Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. Pharmacogenetics 5:275-280